As GLP-1 receptor agonists like semaglutide and tirzepatide become among the most prescribed medications globally, understanding their full side-effect profile matters enormously — not just for clinicians, but for the tens of millions of adults now using these drugs for weight management. Hair loss has emerged as a frequently reported patient complaint, yet its true incidence and causality relative to the drug itself versus the underlying rapid weight loss has remained contested. This meta-analysis attempts to quantify that risk more rigorously than any single trial could.
Pooling data from nine interventional studies — seven randomized controlled trials and two prospective nonrandomized studies — encompassing 4,114 GLP-1 RA users, the analysis found that GLP-1 RA use was associated with a risk ratio of approximately 3.25 for hair loss compared to placebo (95% CI: 1.44–7.36). When restricted to RCTs in overweight or obese populations, the risk ratio climbed to 3.59 (95% CI: 2.10–6.12). A single-arm analysis estimated the absolute event rate of hair loss at roughly 3.9% among GLP-1 RA users.
The mechanistic picture here is genuinely complex. Rapid caloric restriction triggers telogen effluvium — a well-characterized diffuse shedding pattern — meaning the dramatic weight loss induced by GLP-1 drugs could be the proximate cause rather than any direct pharmacological action of the receptor agonist itself. Disentangling these two pathways in trial populations where both occur simultaneously is methodologically difficult, and this meta-analysis cannot fully resolve that confound. The nine included studies represent a relatively modest evidence base, and heterogeneity across populations, drug types, and follow-up durations likely inflates uncertainty around the pooled estimates. Nonetheless, the consistency of the finding across RCTs adds meaningful weight to what many patients have already self-reported. For healthcare providers counseling patients initiating GLP-1 therapy, this quantified risk warrants proactive discussion, particularly regarding nutritional adequacy — protein and micronutrient intake — during active weight loss phases.